IMMUNOLOGICAL CRITERIA OF THE COURSE OF NON-HODGKIN’S LYMPHOMAS
*Tillyashaykhov M. N., Abdiganieva S. R., Tuidzhanova Kh. Kh. and Isroilova F. Kh.
The purpose of this study was to study the main cellular and humoral criteria for the course of non-Hodgkin's lymphomas. An analysis of the results revealed significant changes in the cellular immunity that manifested themselves by suppressing the expression of CD3, CD3, CD4, IRI, against this background, an increase in the expression of CD3 CD8, CD16 and CD20 B cells, as well as increased expression of activation molecular markers of lymphocytes CD38, CD95. A deep T-cell immunodeficiency was detected against the background of pathological activation of lymphocytes, which is clinically often reflected by frequent relapses, an unfavorable course of the disease and the results of therapy. Serum concentrations of the main immunoglobulins IgG, IgA, IgM in NHL were analyzed. The highest serum content of IgG and IgA was revealed in the groups of patients with virus carrier. It has been established that one of the most important humoral markers of immunity is the circulating immune complexes (CICs). It has been established that one of the most important biological functions of immunoglobulins is antigen binding and the formation of CIC. A high level of CIC in NHL may be due not only to the activation of the immune response, but also to the suppression of the mechanisms of their elimination. Therefore, based on the results obtained, with NHL there is a pronounced imbalance of humoral immunity. CIC of large and small sizes are also increased, however, the highest increase in CIC was observed in groups of patients before chemotherapy with virus-bearing. An increase in the main immunoglobulins indicates the presence of humoral imbalance, and an increase in the CIC indicates the presence of intoxication of the body either due to the decay of the tumor cells and infected cells themselves, which almost always indicates the progression of the pathological process.
Keywords: Immune system, adaptive immunity, polychemotherapy, immunocompetent cells, lymphomas, non-Hodgkin lymphoma.
[Full Text Article]